stockrowEli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company (LLY) Total debt
Eli Lilly and Company's total debt at the end of fiscal 2025 was $40.9B, up 43.3% from $28.5B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $47.0B. Over the past ten years it has ranged from $8.0B (fiscal 2015) to $40.9B (fiscal 2025) — the current reading is the highest in ten years. Eli Lilly and Company ranks 5th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $40.9B | 43.26% |
| FY2024 | $28.5B | 55.71% |
| FY2023 | $18.3B | 24.31% |
| FY2022 | $14.7B | (3.97%) |
| FY2021 | $15.3B | (7.53%) |
| FY2020 | $16.6B | 7.49% |
| FY2019 | $15.4B | 49.92% |
| FY2018 | $10.3B | (24.54%) |
| FY2017 | $13.6B | 32.44% |
| FY2016 | $10.3B | 29.26% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $47.0B | (14.43%) |
| Jun 2026 | $54.9B | 39.47% |
| Mar 2026 | $39.4B | (7.37%) |
| Dec 2025 | $42.5B | 3.99% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ABBV AbbVie Inc. compare | $80.9B |
| PFE Pfizer Inc. compare | $62.7B |
| AMGN Amgen Inc. compare | $54.0B |
| MRK Merck & Co., Inc. compare | $51.1B |
| LLY Eli Lilly and Company | $47.0B |
| NVS Novartis AG compare | $46.3B |
| JNJ Johnson & Johnson compare | $35.8B |
| AZN AstraZeneca PLC compare | $31.4B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement